28. Secondary endpoints included change in body weight from base-line to week 28; change in 2-hour postprandial glucose (PPG) afterthe MTT at week 28; proportion of patients with HbA1c <7.0%(<53 mmol/mol) at week 28; change in total mean daily IG dose frombaseline to week 28; proportion of patients with HbA1c <7.0% (<53 mmol/mol) at week 28, with no body weight gain at week 28 and no major hypoglycaemia over the 28-week treatment period;and change in systolic blood pressure (SBP) from baseline atweek 28. Exploratory endpoints included changes in HbA1c and FPG at each visit between baseline and week 28; change from baseline to week28 in FPG, waist circumference, diastolic blood pressure (DBP) andfasting lipids (total, low-density lipoprotein, high-density lipoprotein[HDL] and non-HDL cholesterol, and triglycerides); and patient- reported outcome measures including the Diabetes Treatment Satisfac- tion Questionnaire, status version (DTSQ-s) 29and the Study to Help